Subscribe To

Price Alert Latest News Economic Calendar News

GNFT / Genfit shares fall despite positive trial results for rare cholestatic liver disease therapeutic

GENFIT (NASDAQ:GNFT) shares fell 5% after initially rising on positive results from its clinical trial with partner Ipsen for the investigational therapeutic elafibranor in patients with the rare cholestatic liver disease primary biliary cholangitis (PBC). The two companies announced on Friday that the Phase 3 ELATIVE trial met its primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to the placebo. Read More

Demo Live Account See Partner Details

Content Topics

Genfit

Fall

Despite

Positive

Trial

Results

Rare

Cholestatic

Disease

Therapeutic

Stock

GNFT

Posted: Jun 30 2023, 10:46

Author Name: Proactive Investors

GNFT News

By GlobeNewsWire
November 2, 2023

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage bio

By GlobeNewsWire
September 5, 2023

GENFIT to Participate in Upcoming Investor Conferences

Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) , September 05 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT), a late-

By Proactive Investors
June 30, 2023

Genfit shares fall despite positive trial results for rare cholestatic liver disease therapeutic

GENFIT (NASDAQ:GNFT) shares fell 5% after initially rising on positive results from its clinical trial with partner Ipsen for the investigational the

By Market Watch
June 30, 2023

U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease

The U.S.-listed stock of Genfit S.A. GNFT, -5.48% GNFT, +22.56% soared 27% premarket Friday, after the French biotech and partner Ipsen IPSEY, +7.22%

By Seeking Alpha
February 10, 2023

Genfit: Catching Strong Bid With Emerging Data (Technical Analysis)

Genfit is a relatively low-beta play offering investors tactical upside with a potential re-rating to the upside. Investors have rewarded the company'

By Seeking Alpha
September 7, 2022

Genfit S.A.: A 'Sum Of The Parts' Story

Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving

By Seeking Alpha
April 8, 2022

Genfit SA (GNFT) CEO Pascal Prigent on Q4 2021 Results - Earnings Call Transcript

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.